Physician profile
Jonathan H Taylor
NPI 1114134780
$6,457.60
in general payments reported to CMS, 2019-2025
27 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $976 · 2020: $664 · 2021: $686 · 2022: $1,115 · 2023: $774 · 2024: $1,008 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,016.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $2,265.81 | 2019-2025 | Provenge |
| Teleflex LLC | $557.65 | 2022-2024 | Urolift |
| Astellas Pharma US INC | $543.09 | 2019-2024 | Xtandi |
| Boston Scientific Corporation | $523.66 | 2019-2025 | Axonics, Spaceoar Vue System - 10ml |
| Janssen Biotech, INC. | $382.46 | 2019-2023 | |
| Axonics, INC. | $362.06 | 2021-2024 | Axonics |
| Laborie Medical Technologies Corp. | $259.82 | 2019-2025 | |
| Medtronic, INC. | $238.62 | 2022-2025 | Interstim |
| Bayer Healthcare Pharmaceuticals INC. | $228.18 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $193.46 | 2019-2021 | |
| Abbvie INC. | $134.65 | 2019-2025 | Botox |
| Neotract INC. | $121.68 | 2019-2020 | |
| Pfizer INC. | $116.52 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $107.86 | 2025 | Keytruda |
| Intuitive Surgical, INC. | $89.92 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $48.26 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $47.89 | 2025 | Gemtesa |
| Arrow International, INC. | $46.67 | 2022 | |
| Tolmar, INC. | $43.50 | 2024 | |
| Allergan, INC. | $39.48 | 2019-2021 | |
| Siemens Medical Solutions USA, INC. | $24.04 | 2025 | Somatom X.Cite |
| Ferring Pharmaceuticals INC. | $23.71 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $20.46 | 2022 | |
| Coloplast Corp | $13.96 | 2019 | |
| Amgen INC. | $13.14 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $11.05 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.